DRUG
Placebo
matching Placebo Capsules, Oral, once daily
Status
Completed
Phase
Phase 3
Enrollment
1,722
Locations
82
Results
Posted
Publications
1
Study summary
This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand. The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).
Interventions
DRUG
matching Placebo Capsules, Oral, once daily
DRUG
Linaclotide 290 ug Capsules, Oral, once daily
Timeline
First posted
Jun 19, 2013
Study start
Jul 2013
Primary completion
May 2015
Study completion
May 2015
Results posted
Sep 27, 2016
Registry updated
Sep 27, 2016
Outcomes
12-week Abdominal Pain/Abdominal Discomfort Weekly Responder
Time frame · Baseline and Weeks 1-12 during the Treatment Period
A 12-week Abdominal Pain/Abdominal Discomfort Responder is a patient who meets the Abdominal Pain/Abdominal Discomfort Weekly Responder criteria (i.e., an improvement of ≥30% from baseline in either the mean abdominal pain score or mean abdominal discomfort score for that week, with neither score worsening from baseline for that week) for at least 6 out of the 12 weeks of the Treatment Period. Abdominal pain at its worst (in the last 24 hours) was assessed daily by patients on an 11-point numerical rating scale (NRS) where 0 represents no abdominal pain and 10 represents very severe abdominal pain. Abdominal discomfort (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal discomfort and 10 represents very severe abdominal discomfort.
12-week Irritable Bowel Syndrome (IBS) Degree of Relief Responder
Time frame · Baseline and Weeks 1-12 during the Treatment Period
A 12-week IBS Degree of Relief Responder is a patient who meets the IBS Degree of Relief Weekly Responder criteria (i.e., response to the degree of relief of IBS symptoms question for that week was "Considerably relieved" or "Completely relieved") for at least 6 out of the 12 weeks of the Treatment Period. Degree of relief of IBS symptoms (in the last 7 days) was assessed weekly by patients on a 7-point balanced ordinal scale where 1 = Completely relieved, 4 = Unchanged, and 7 = As bad as I can imagine.
Change From Baseline in 12-week Complete Spontaneous Bowel Movement Frequency Rate
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week CSBM frequency (i.e., average weekly CSBM frequency over the 12 weeks of the Treatment Period). A spontaneous bowel movement (SBM) is defined as a bowel movement without laxative use in the preceding 24 hours. A CSBM is defined as an SBM that is associated with a sense of complete evacuation.
Change From Baseline in 12-week Spontaneous Bowel Movement Frequency Rate
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week SBM frequency (i.e., average weekly SBM frequency over the 12 weeks of the Treatment Period). SBM is defined as a bowel movement without laxative use in the preceding 24 hours.
Change From Baseline in 12-week Stool Consistency
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week stool consistency (i.e., the average of the non-missing Bristol Stool Form Scale \[BSFS\] score from the SBMs occurring during the 12-week Treatment Period). Consistency of each bowel movement was assessed daily by patients using the 7-point BSFS (1=Separate hard lumps like nuts \[difficult to pass\] to 7=Watery, no solid pieces \[entirely liquid\]).
Change From Baseline in 12-week Severity of Straining
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week severity of straining (i.e., the average of the non-missing straining scores from the SBMs occurring during the 12-week Treatment Period). Severity of straining was assessed daily by patients on a 5-point ordinal scale (1=Not at all to 5=An extreme amount).
Change From Baseline in 12-week Abdominal Bloating
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week abdominal bloating (i.e., the average of the non-missing daily abdominal bloating scores reported during the 12-week Treatment Period). Abdominal bloating (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal bloating and 10 represents very severe abdominal bloating.
Change From Baseline in 12-week Abdominal Pain
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week abdominal pain (i.e., the average of the non-missing daily abdominal pain scores reported during the 12-week Treatment Period). Abdominal pain at its worst (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
Change From Baseline in 12-week Abdominal Discomfort
Time frame · Baseline and 12-week Treatment Period
The change from baseline in 12-week abdominal discomfort (i.e., the average of the non-missing daily abdominal discomfort scores reported during the 12-week Treatment Period). Abdominal discomfort (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal discomfort and 10 represents very severe abdominal discomfort.
Eligibility
Inclusion Criteria: 1. Patient has signed an Informed Consent Form(ICF). 2. Patient Must not be pregnant or breastfeeding and agree to use birth control 3. Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings; 4. Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria 5. Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms Exclusion Criteria: 1. Recent history of mushy or watery stools 2. Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study 3. Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis. 4. Surgery to the gastrointestinal tract 5. Usage of prohibited medications
Study locations
Australia · Canada · China · New Zealand · United States. Showing up to 24 locations stored in the fast local snapshot.
Research Site
Huntsville, Alabama, United States
Research Site
North Little Rock, Arkansas, United States
Research Site
Phoenix, Arkansas, United States
Research Site
Artesia, California, United States
Research Site
Chula Vista, California, United States
Research Site
Encino, California, United States
Research Site
North Hollywood, California, United States
Research Site
Orange, California, United States
Research Site
Riverside, California, United States
Research Site
San Diego, California, United States
Research Site
Boynton Beach, Florida, United States
Research Site
Brandon, Florida, United States
Research Site
Brooksville, Florida, United States
Research Site
Doral, Florida, United States
Research Site
Gainesville, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Kissimmee, Florida, United States
Research Site
Lauderdale Lakes, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Addison, Illinois, United States
Research Site
Evansville, Indiana, United States
Research Site
Crowley, Louisiana, United States
Research Site
Monroe, Louisiana, United States
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.